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Abstract: There are many known endocrine complications after allogeneic hematopoietic stem
cell transplantation (HSCT) in childhood including increased risk of biochemical hypogonadism.
However, little is known about sexuality in adulthood following childhood HSCT. In this multicenter
study, sexual functions and possible risk factors were assessed comprehensively in two national
cohorts (Finland and Denmark) of male adult survivors of childhood HSCT. Compared to a healthy
control group (n = 56), HSCT survivors (n = 97) reported less sexual fantasies, poorer orgasms, lower
sexual activity with a partner and reduced satisfaction with their sex life, even in the presence of
normal erectile functions and a similar frequency of autoerotic acts. Of the HSCT survivors, 35%
were cohabitating/married and 66% were sexually active. Risk factors for poorer self-reported sexual
functions were partner status (not cohabitating with a partner), depressive symptoms, CNS and
testicular irradiation. Sexual dysfunction increased by age in the HSCT group with a pace comparable
to that of the control group. However, because of the lower baseline level of sexual functions in the
HSCT group, they will reach the level of clinically significant dysfunction at a younger age. Hence,
male survivors of childhood HSCT should be interviewed in detail about their sexual health beyond
erectile functions.
Keywords: HSCT; children; long-term survivors; pediatric cancer; sexual dysfunction; late effects
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1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure
for a number of malignant and non-malignant hematological disorders. Despite the great improvements
in clinical practices in recent decades, nearly all children treated with HSCT will experience one or
more treatment-related late effects [1]. Those most frequently observed are endocrine complications
such as hypogonadism, impaired fertility, growth delay and metabolic disturbances [2]. However,
there is very little knowledge about sexual health in adulthood.
In adult survivors of childhood HSCT, sexual functions have previously only been reported on a
general level as one of several aspects of quality of life. Pediatric HSCT survivors have rated family
and relationships with a partner among the top 10 important areas in life [3]. However, compared to
their peers, an increased proportion of these survivors are living with their parents and have never
been married or cohabitated with a partner [4]. One study identified sexual functions and partner
relations among the most affected areas of long-term quality of life [5].
In adult male HSCT recipients, an initial decline in sexual activity and sexual functions have been
reported after HSCT with the majority experiencing recovery by 1–2 years post-HSCT. However, even
five years after HSCT, recipients continued to report significantly lower sexual functions compared to
peers [6]. Problems with erection, ejaculation and orgasm, pain during intercourse, diminished sexual
interest and anxiety about sexual performance dominate [6–8].
Male cancer survivors, with or without HSCT, generally tend to participate less in studies and also
report less psychological and sexual dysfunction compared to females [4,9,10]. In this national cohort
study of two Nordic countries (Denmark and Finland), we therefore focused on a systematic evaluation
of sexual functions in male adult survivors of childhood HSCT and associations to sociodemographic
factors, therapy exposures, physical and psychological health.
2. Results
2.1. Clinical Data and Sex Hormones
At the time of HSCT, 71 patients were prepubertal, 16 pubertal and 9 post-pubertal (data not
known for one patient). At the time of this study, all were post-pubertal (Tanner stages 4–5). Genital
chronic graft-versus-host disease (cGvHD) was found in 16 patients; 11 were operated for phimosis
that emerged after HSCT, 1 was operated for urethral stenosis that emerged after HSCT, 2 had lichen
sclerosis, 1 had lichen planus like changes and was operated for phimosis that emerged after HSCT
and 1 had a maculopapular rash on scrotum. Compared to the control group, the HSCT group had
significant testicular damage, indicated by lower testosterone levels, lower testicular volumes and
lower total sperm counts and more socioeconomic disadvantage, i.e., living without a partner, lower
education and more unemployment (Table 1).
Table 1. Background and laboratory characteristics in pediatric hematopoietic stem cell transplantation
(HSCT) survivors and controls.
Characteristic HSCT(n = 97) Range
Controls
(n = 56) Range p-Value
Background variables Mean (SD) Mean (SD)
Age at assessment 28.8 (7.3) 18.5–47.0 29.6 (3.2) 24.0–36.0 0.334
Age at diagnosis 8.7 (4.4) 0.2–16.4
Age at HSCT 9.8 (4.2) 0.4–16.9
Follow-up time since HSCT 19.0 (7.0) 7.7–34.6
Diagnostic groups n (%)
ALL 45 (46%)
NHL 5 (5%)
AML 9 (9%)
SAA 14 (14%)
Other 24 (25%)
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Table 1. Cont.
Characteristic HSCT(n = 97) Range
Controls
(n = 56) Range p-Value
Social and demographic variables n (%) n (%)
Married or cohabitating 34 (35%) 45 (80%) <0.001
Biological children 6 (6%) 24 (43%) <0.001
Highest education <0.001
Comprehensive school (9 years) 20 (21%) 3 (5%)
Matriculation examination or vocational
school (12 years) 50 (52%) 20 (36%)
Lower tertiary education (15 years) 13 (13%) 23 (41%)
Higher tertiary education (min. 17 years) 14 (14%) 10 (18%)
Employment 0.009
Employed/student (full or part time) 85 (88%) 56 (100%)
Treatment regimens n (%)
Cancer treatment prior to HSCT 65 (67%)
Total body irradiation 71 (73%)
Median
Cumulative gonadal irradiation dose (cGy) 1000 0–4130
Cumulative CNS irradiation dose (cGy) 1000 0–3600
Cumulative cyclophosphamide equivalent
doses (mg/m2) 1 5113 0–28,743
Laboratory variables Median Median
Inhibin B (ng/L) 3 21.0 1.0–247.0 157.0 74.0–307.0 <0.001
FSH (IU/L) 9.8 0.01–64.4 3.2 0.9–11.4 <0.001
LH (IU/L) 5.0 0.01–31.0
SHBG (nmol/L) 1 26.4 4.8–68.8 32.5 13.0–70.0 0.004
Prolactin (mU/L) 209 44–888 216 101–634 0.350
TSH (mU/L) 2.5 0.03–9.8
Total testosterone (nmol/L) 15.4 1.7–53.8 18.4 7.1–32.6 0.010
Free testosterone (pmol/L) 1 350 38–1470 296.5 151–406 0.002
Mean testicular volume (mL) 2 13.5 2.0–27.0 33.9 22.2–63.9 <0.001
Total sperm count, millions 4 0.00 0.00–524.8 135.5 17.0–562.0 <0.001
Treatment-related variables n (%)
Azoospermia, n (%) 5 61 (67%) 0 <0.001
Ongoing testosterone substitution 24 (25%) 0 <0.001
Ongoing thyroxin substitution 25 (26%)
Chronic GvHD at the time of assessment 27 (28%)
Grade 1 13 (13%)
Grade 2 11 (11%)
Grade 3 3 (3%)
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CNS, central nervous system;
FSH, follicle-stimulating hormone; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation;
LH, luteinizing hormone; SHBG, sex hormone-binding globulin; TSH, thyrotropin; NHL, non-Hodgkin lymphoma;
SAA, severe aplastic anemia. Data are presented as the mean (SD) and range with p-values from independent
samples t test, median and range with p-values from independent samples Mann–Whitney U test, or n (%) with
p-values from the exact χ2 test. 1 Data missing for one HSCT patient. 2 Data missing for four HSCT with bilateral
orchiectomy, and four controls. 3 Data missing for four controls. 4 Data missing for six HSCT patients and two
controls. 5 Data missing for six HSCT patients.
2.2. Sexual Functioning
Of the 97 HSCT survivors, 63 (66%) reported to be sexually active (data not known for one patient).
Of the 63 survivors not cohabitating with a partner, 29 (47%) were sexually active, while the percentage
was 100% for the 34 men cohabitating with a partner. These data were not known for the control group.
The HSCT and control groups were compared in a MANCOVA test regarding self-reported
sexual functioning. After adjustment for age at assessment and employment status, a significant main
effect of group was found for overall sexual functioning; F(5, 143) = 3.34, p = 0.007, Wilk’s Λ = 0.895,
ηp
2 = 0.105. In Bonferroni-corrected univariate analyses, the HSCT group reported poorer functioning
in all domains except sexual arousal (Table 2).
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Table 2. Mean values (SD) in the Derogatis Interview for Sexual Functioning self-report between
HSCT survivors and a healthy control group, with domain p-values from MANCOVA with
Bonferroni-corrected post-hoc tests and item p-values from independent samples t tests corrected with
the false discovery rate.
Domain Item HSCT (n = 97) Controls (n = 56) p-Value
Sexual fantasy (about) 22.6 (9.2) 25.8 (6.6) 0.023
Attractive person 5.1 (2.0) 5.8 (1.6) 0.074
Erotic parts of a woman 5.0 (2.0) 5.5 (2.1) 0.675
Erotic situation 4.4 (2.0) 5.0 (1.6) 0.204
Foreplay 4.0 (2.2) 4.8 (1.8) 0.029
Intercourse 4.1 (2.3) 4.8 (1.6) 0.074
Sexual arousal (Full erection) 16.5 (6.5) 17.3 (5.9) 0.423
When waking up 3.2 (1.8) 3.4 (1.9) 1.00
During a fantasy 3.4 (2.0) 3.6 (2.1) 1.00
During a visual cue 3.8 (1.8) 3.4 (1.7) 0.651
During masturbation 3.8 (1.6) 3.5 (1.6) 0.342
During intercourse 2.3 (2.0) 3.2 (1.7) 0.002
Sexual behavior 13.3 (7.0) 17.3 (4.7) 0.016
Erotic books 2.6 (2.0) 2.0 (1.9) 0.310
Masturbation 3.7 (1.5) 3.2 (1.6) 0.216
Kissing and petting 3.0 (2.7) 5.4 (2.0) <0.001
Foreplay 2.1 (2.0) 3.4 (1.8) <0.001
Intercourse 2.0 (2.0) 3.3 (1.7) <0.001
Orgasm 15.3 (5.6) 18.6 (3.8) 0.002
Ability 2.8 (1.1) 3.4 (0.9) 0.006
Intensity 2.7 (1.0) 3.2 (0.7) 0.002
Duration 2.5 (1.1) 3.0 (0.9) 0.006
Amount of seminal fluid 2.2 (1.2) 3.0 (0.9) <0.001
Sense of control 2.3 (1.1) 2.7 (0.8) 0.078
Feeling of relaxation afterward 2.8 (1.0) 3.3 (0.9) 0.006
Sexual drive 13.4 (4.4) 15.3 (3.4) 0.022
Ideal frequency of intercourse 4.6 (1.7) 4.5 (0.8) 1.00
Interest in sex 2.4 (0.9) 2.8 (0.7) 0.075
Satisfaction with personal relationship 1.8 (1.5) 2.6 (1.1) <0.001
Quality of current sexual functioning 4.5 (2.2) 5.5 (1.8) 0.012
Note. Scoring ranges for individual domains are: 0–40 for sexual fantasy, arousal and behavior; and 0–24 for orgasm
and drive. Higher scores indicate better sexual functioning. Domain scores are indicated in bold.
The MANCOVA also revealed a significant interaction between group and cohabitation status;
F(5, 143) = 3.54, p = 0.005, Wilk’s Λ = 0.890, ηp2 = 0.110. Bonferroni-corrected pairwise comparisons
indicated that all men cohabitating with a partner, irrespective of group, reported similar sexual
functioning. However, HSCT survivors not cohabitating with a partner had significantly poorer sexual
functions compared to controls not cohabitating, regarding sexual fantasy (p = 0.002), sexual behavior
(p < 0.001), orgasm (p < 0.001) and sexual drive (p = 0.004) (Figure 1).
Concerning covariates included in the MANCOVA, there was no main effect of employment status
on sexual functions. However, there was a main effect of age, with older men reporting poorer sexual
functions across HSCT and control groups; F(5, 143) = 4.66, p = 0.001, Wilk’s Λ = 0.860, ηp2 = 0.140.
The effect was significant for sexual arousal (p = 0.015), orgasms (p < 0.001) and drive (p = 0.017).
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To analyze the effect of age between the HSCT and control groups, an age category (18–27, 28–
30 and 31–47 years) was added as an independent variable in an additional MANCOVA. No group 
× age interaction emerged, indicating that sexual functions decreased with a similar pace in both 
groups; F(10, 272) = 0.375, p = 0.957, Wilk's Λ = 0.973, ηp2 = 0.014 (Figure 2). 
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Figure 1. Mean scores on the Derogatis Interview for Sexual Functioning self-report (DISF-SR) in HSCT
survivors and their controls categorized by partner status.
To analyze the effect of age between the HSCT and control groups, an age category (18–27, 28–30
and 31–47 years) was added as an independent variable in an additional MANCOVA. No group × age
interaction emerged, indicating that sexual functions decreased with a similar pace in both groups;
F(10, 272) = 0.375, p = 0.957, Wilk’s Λ = 0.973, ηp2 = 0.014 (Figure 2).
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Figure 2. Mean total scores on the Derogatis Intervi w for Sexual Functioning self-report (DISF-SR) in
HSCT survivors and their controls. Results are categorized according to age group. Sexual functions
declined in a similar pace in both groups.
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2.3. Risk Factors for Reduced Sexual Functions within the HSCT Group
Regression analyses were carried out only within the HSCT group. Overall, self-reported
depressive symptoms and CNS irradiation exposure were the single most important risk factors for
poorer sexual functions (Table 3). Leydig cell function was associated with sexual cognition with the
poorest scores observed in the survivors with ongoing testosterone substitution and the highest scores
in those with normal serum testosterone levels (≥10 nmol/L). Similarly azoospermia correlated with
poorer sexual function but since testosterone substitution affects spermatogenesis, azoospermia as an
independent predictor was excluded from further analyses.
The treatment variables CNS and testicular irradiation made the model unstable due to their
high multicollinearity. To analyze the effect of the multicollinearity, CNS and testicular irradiation
exposure doses were included in the regression model one by one together with the other independent
variables. These analyses showed that the multicollinearity affected the domain of sexual arousal and
orgasm; cumulative doses of CNS and testicular irradiation replaced each other if only one of them
was included in the analyses.
Table 3. Multiple regression analyses of risk factors associated with self-reported sexual functions in
the Derogatis Interview for Sexual Functioning self-report among HSCT survivors (n = 94).
Domain Risk Factors Standardized β Adjusted R2
Sexual cognition/fantasy BDI-21 −0.234 * 0.094
Testosterone group 0.214 *
Sexual arousal a 0.146
BDI-21 −0.289 **
CNS irradiation exposure −0.215 *
Sexual behavior/experience b 0.043
CNS irradiation exposure −0.231 *
Orgasm c 0.368
BDI-21 −0.431 ***
CNS irradiation exposure −0.240 **
Age −0.206 *
Sexual drive/relationship 0.196
BDI-21 −0.453 ***
Abbreviations: BDI-21, Beck Depression Inventory; CNS, central nervous system. Note. The model included the
following independent variables: age, education level, age at HSCT, cumulative cyclophosphamide equivalent
dose, cumulative testicular and CNS irradiation exposure, testosterone group, cGvHD, two-minute walk test and
BDI-21. In the DISF-SR, higher scores indicate better sexual functioning, while in BDI-21, lower scores indicate less
depressive behavior. a When CNS irradiation was excluded from the analysis, BDI (β −0.326; p < 0.01) and testicular
irradiation exposure (β −0.195, p < 0.05) had a significant association (adjusted R2 = 0.140). b When CNS irradiation
was excluded from the analysis, no associations to risk factors emerged. c When CNS irradiation was excluded from
the analysis, BDI (β −0.477; p < 0.001), age (β −0.198; p < 0.05) and testicular irradiation exposure (β −0.180, p <
0.05) had a significant association (adjusted R2 = 0.345). *** p < 0.001, ** p < 0.01, * p < 0.05.
3. Discussion
This is the first study using a standardized questionnaire to assess multiple domains of sexual
functions in adult male survivors of childhood HSCT. Several domains of sexuality were affected.
HSCT survivors had less sexual fantasies, engaged less in sexual activity together with a partner,
had poorer orgasms, experienced erectile problems during intercourse and were less satisfied with their
personal relationships compared to age-matched peers. However, survivors had a similar frequency of
autoerotic acts and were capable of a full erection during these activities, indicating an interrelational
rather than merely a physiological problem.
Relationship status was strongly associated with sexual dysfunction. In line with previous studies,
only 35% of the survivors were married or cohabitating [3,4]; a concern raised also among long-term
survivors of childhood cancers treated without HSCT [11,12]. Moreover, half of the HSCT recipients
living alone reported not being sexually active. In adult cancer survivors, the presence of a partner and
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a better post-treatment recovery of sexual functions are associated [13]. Hence, finding a partner is an
important psychosexual milestone for these young survivors.
In a previous study of adult HSCT recipients, 25% of men reported erectile dysfunction often or
always [7]. In the present study, the recipients of pediatric HSCT reported full erection during sexual
fantasies and autoerotic acts, yet erectile dysfunction during intercourse and less frequent sexual
activity with a sexual partner. This discrepancy has also been reported in conventionally treated adult
male survivors of childhood cancer [11]. Our data indicate that for survivors of pediatric HSCT, sexual
functions with a partner are particularly affected, even in the presence of normal erectile function.
This observation supports the notion that problems with partner relationships are a major obstacle in
decreased sexual functioning after pediatric HSCT.
Higher cumulative doses of radiotherapy exposing the CNS or testicles had an effect on the
physical quality of arousal and orgasms, while sexual behavior was affected more by CNS irradiation.
Radiotherapy exposing the CNS has an adverse effect on the hypothalamic–pituitary–gonadal axis,
thyroid function and long-term sequelae on cognition. This may potentially affect sexual desire
and the ability to form partnerships through hormonal abnormalities, short stature and cognitive
impairment [14]. Similarly, radiotherapy exposing gonads may cause hypogonadism leading to
azoospermia, Leydig cell damage and decreased serum testosterone, as well as direct irradiation
damage to the spinal cord, sympathetic nerves or pelvis leading to physical sexual dysfunction [15].
Indeed, ongoing testosterone substitution, as a sign of significant hypogonadism, was associated
with lower sexual cognition. The reasons for this association could not be explored in this study,
but we observed greater variations in testosterone levels in the substituted group, compared to the
non-substituted men. For some of the men, the testosterone substitution may not have been optimal.
Further, the psychological burden associated with infertility may explain some of the observed sexual
dysfunction [16]. No association between cumulative doses of alkylating agents and sexual function
was observed. This is in line with the evidence that alkylating agents do not cause overt testosterone
deficiency in early adulthood and, hence, have no independent effect on sexual function [15].
Self-reported depressive symptoms were strongly associated with dissatisfaction with sexual
functioning. Depression and anxiety have been related to sexual dysfunction in adult recipients of
HSCT [8] as well as in the general population [17]. The effect of depression and sexual dysfunction is
best understood as bidirectional, both conditions affecting each other.
Physical consequences such as endurance, measured by an objective test of walking distance over
two minutes, or cGvHD, graded on the day of examination, were not associated with self-reported
sexual functioning. Chronic GvHD has been associated with sexual dysfunction in some studies [18],
while not in others [19]. However, adult recipients with genital cGvHD have reported more erectile
dysfunction [20]. Genital cGvHD was rare in our patient sample, with no severe (Score 3) forms
detected. Similarly, severe cGvHD was found in only 3%, while mild (Score 1) and moderate (Score 2)
forms together were detected in almost one fourth of the sample. The present results suggest that
psychosexual consequences, rather than physical functions alone, predict sexual dysfunction in
this population.
Sexual function declines with age in the general population, an effect also observed in this study.
Older age at assessment was associated with more functional problems in the domains of arousal and
orgasm as well as with sexual drive. The difference between the HSCT and control groups remained
stable over time. Age or pubertal status at HSCT, educational level or employment status were not
associated with sexual health in this study. In sum, age, but not other demographic risk factors, was
important for long-term sexual outcome. Due to their lower initial level of sexual functions, the HSCT
recipients are expected to reach the level of clinically significant dysfunction at a younger age than
their healthy peers.
The consequences of HSCT on sexual functioning are not routinely discussed at health care visits.
In adult HSCT recipients approximately half of the patients reported that their health care provider
had discussed consequences on sexual functioning (excluding fertility) [21] while the number was as
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low as 38% in adult survivors of childhood HSCT [5]. Patients wish for the initiative for discussions on
sexual matters to come from health care professionals [5]. The high response and participation rates in
our study suggest that long-term survivors of pediatric HSCT are interested in their gonadal function.
Since it may be uncomfortable for many patients to bring up sexual matters, it is important for health
care providers to ask about genital skin symptoms, partners and sexual dysfunction. Clinicians need
structured guidelines how to interview young survivors about their sexual health.
A limitation of this study was that the control group was recruited from occupational health
services, and all were employed. The employment rate of 88% in the HSCT survivors was similar
to those reported by others (82–86%) [4,22]. Employment status was controlled for in the group
comparisons and was not associated with sexual functions. Hence, it does not appear to have skewed
the results. Further, the control group was collected 9 years prior to the patient group. An important
extension of this study would be to assess the experiences of the survivors’ partners. This would offer
a valuable point of view for studying the more well-functioning HSCT survivors in more detail. Our
response (70%) and participation rates (54%) were good considering the extensive evaluations to which
the participants agreed.
4. Materials and Methods
This study is part of a larger cross-sectional cohort study addressing long-term gonadal function,
metabolism, immune function, physical fitness, sexual health and quality of life. It included two
national cohorts of men who before the age of 17 years had undergone HSCT in Denmark or Finland
between 1980 and 2010 and who were at least 18 years by 1st of January 2017. Patients were excluded
from this study if they were unable to give informed consent, if language difficulties compromised
the examinations or if patients had undergone more than one HSCT. In the Finnish cohort, all eligible
patients were contacted by mail. In the Danish cohort, this was carried out by mail and phone.
A total of 181 eligible patients were identified—of which 55 could not be reached. Of the
126 patients who were contacted, 5 were excluded because they were unable to give informed consent
(4 due to intellectual disability and 1 due to language difficulties) and 24 declined participation in
this substudy. Thus, 97 survivors (49 Danish and 48 Finnish) participated in this study, giving a
participation rate of 54%. Altogether, 59 (60%) of the participants had a malignant diagnosis. There
were no statistically significant differences in the numbers of malignancies, age at HSCT, follow-up time
or other transplant characteristics between participants and non-participants [23] (data not shown).
The examination consisted of an updated medical anamnesis, questionnaires, laboratory measurements
and a physical examination. All examinations were carried out between January and October 2017.
An age- and gender-matched control group was recruited from the occupational health services of
the Helsinki municipality area and the Helsinki University Central Hospital. A total of 56 men without
a history of cancer or HSCT participated. They underwent the same examinations between August
2005 and June 2008.
4.1. Self-Report Measure of Sexual Functioning
Sexual functioning was assessed by the Derogatis Interview for Sexual Functioning self-report
(DISF-SR) [24]. It comprises 25 questions which form five domains: sexual cognition/fantasy (5 questions
on the frequency of sexual thoughts and fantasies), sexual arousal (5 questions on the frequency of a full
erection during, e.g., sexual fantasies, masturbation and sex), sexual behavior/experience (5 questions
on the frequency of sexual acts such as engaging in books/films with erotic content, masturbation,
foreplay and intercourse), orgasm (6 questions on how content the respondent is with his orgasms)
and sexual drive/relationship (4 questions about the ideal frequency of sexual intercourse, interest in
sex, satisfaction with the current sexual relationship and quality of sexual functioning). The questions
were rated on a five- or nine-point Likert scale. Total scores were calculated for each domain as well as
a global summary score (total score). Higher scores indicate better functioning and a higher sexual
activity level.
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4.2. Risk Factors
Data on relationship status and sexual activity were collected during a structured interview,
while other background and social variables were collected by questionnaire. Self-reported depressive
symptoms were evaluated with the Beck Depression Inventory (BDI-21) [25]. It comprises 21 questions
rated on a four-point Likert scale. Lower scores indicate fewer depressive symptoms. Since question
number 19 about weight loss was different in the Danish and Finnish versions, it was removed.
The two-minute walk test was used as an objective measure of physical fitness and a z-score was
calculated [26].
The survivors’ medical history was reviewed from medical records including therapeutic pre-HSCT
exposure and exposure at conditioning to irradiation (testicular, CNS and total body irradiation, cGy)
and alkylating agents. Alkylating agents were converted into a cumulative cyclophosphamide
equivalent dose (CED, mg/m2) [27].
Testicular volume and hormone levels were assessed on the day of examination. Blood samples
were taken before 10 a.m. and analyzed in the laboratories of the Helsinki University Hospital and
Rigshospitalet according to the hospitals’ routine methods. Free testosterone was calculated from
total testosterone and SHBG, with a fixed albumin level of 43 × 8 g/L [28]. Testicular volume was
measured by an orchidometer (mL). Mean volume of the testicles was calculated, when applicable.
Chronic GvHD was assessed by examination according to the National Institutes of Health criteria [29].
Previous phimosis or urethral stenosis that emerged after transplantation, but was later surgically
removed, was considered a diagnostic sign of cGvHD with genital symptom score 1. The methods
have been described in more detail in Mathiesen et al. [23].
4.3. Statistical Analyses
Statistical calculations were carried out using IBM SPSS Statistics 24.0. Group comparisons of the
background variables were undertaken with independent samples t test, Mann–Whitney U test and
Fisher’s exact χ2 test.
Sexual functioning was analyzed in a MANCOVA, with the five DISF-SR domain scores
as the dependent variables. The domain scores were normally distributed by visual inspection.
The independent variables were group (HSCT and control group) and cohabitating with a partner
(yes/no). Adjustments were made for two covariates: age at assessment and employment status (full- or
part time work or studies, yes/no). Employment status was controlled for because it was significantly
different between the groups. Bonferroni correction was used for post-hoc tests. Additionally, the
DISF-SR questions were analyzed on item level using independent-samples t tests corrected for multiple
comparisons with the false discovery rate.
To assess the effect of age, an additional MANCOVA was undertaken with the DISF-SR domain
scores as dependent variables. The independent variables were group (HSCT vs. control group),
cohabitating with a partner (yes/no) and age category (three classes). The age categories were 18–27
(n = 47), 28–30 (n = 18) and 31–47 years (n = 32). The analysis was adjusted for employment status.
Risk factors were analyzed in forward multiple regression analyses with the DISF-SR domain
scores used as dependent variables in separate analyses. The risk factors included as independent
variables were related to background variables (age at assessment, educational level), treatment (age at
HSCT, CED, total cumulative radiotherapy exposing the testicles and CNS) and physiological, physical
and psychological functioning at the time of assessment (Leydig cell function, cGvHD, two-minute
walk test z-score, BDI-21 score). Three testosterone groups were defined based on Leydig cell function:
(1) ongoing testosterone substitution, (2) low serum testosterone level (<10 nmol/L) and (3) normal
testosterone level (≥10 nmol/L). The mean (SD) testosterone values for the groups were: (1) 20.3
(12.1), (2) 6.6 (2.5) and (3) 17.4 (5.2) nmol/L. Age at assessment and follow-up time were significantly
correlated and only age was included in the regression model. Increased TSH levels correlated with
poorer sexual behavior and drive, but the need for thyroxin substitution had a strong intercorrelation
with CNS irradiation. Hence, TSH levels could not be included in the regression analyses. Tanner
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stage at HSCT, total sperm count, free testosterone, SHBG and prolactin were not correlated with the
DISF-SR and thus not included.
In the HSCT group, there were a total of 14 missing item responses in the DISF-II domain of sexual
drive (3.6% missing data in the domain) in eight patients. Seven of these were sexually inactive and
had not rated their satisfaction with the current sexual relationship. Since most men with inactive
sex lives in this study group had rated this question with the lowest possibly score of 0, these seven
missing replies were given a score of 0. The rest of the missing data (seven item responses) were
estimated using the expectation-maximization algorithm. All tests of significance were two sided
(p < 0.05). ηp2 and R2 served as indicators of effect size.
4.4. Ethics
This study was approved by the Regional Committee on Health Research Ethics, Denmark
(H-16043059), the Danish Data Protection Agency (RH-2017-58), the Helsinki University Hospital
(HUS/1742/2016) and the Research Ethics Committee of the Helsinki University Hospital (DNR no.
1905-32/300/05). All participants provided written informed consent.
5. Conclusions
In conclusion, a standardized questionnaire assessing multiple domains of sexual functions
identified lower sexual activity and poorer orgasms in adult male survivors of childhood HSCT.
Sexual functions with a partner were affected even in the presence of normal erectile function. Sexual
dysfunction was strongly associated with the presence of depressive symptoms, the absence of a
life partner, and cumulative doses of radiotherapy exposing the CNS and the testicles with resulting
azoospermia and reduced testosterone production, but not with cGvHD or physical endurance.
Our results suggest that psychosexual consequences, rather than physical deficiencies, predict sexual
dysfunction in this population. Male survivors without a partner, in particular, should be interviewed
in detail about their sexual health beyond erectile functions.
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